2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2007030321v1 18/11/2863    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Letts, G. Articles by Loscalzo, J. Search for Related Content PubMed PubMed Citation Articles by Letts, G. Articles by Loscalzo, J.

Frontiers in Nephrology: Targeting Inflammation Using Novel Nitric Oxide Donors

Gordon Letts^* and Joseph Loscalzo

^* NitroMed, Inc., Lexington, Massachusetts; and Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts

Correspondence: Dr. Joseph Loscalzo, Brigham & Women's Hospital, 75 Francis Street, Boston, MA 02115. Phone: 617-525-4833; Fax: 617-525-4830; E-mail: jloscalzo{at}partners.org

Chimeric molecules are single-chemical entities that possess at least two separate functions. In the design of new chimeric medicines, the two biologic actions are often designed to be synergistic and, thereby, complement each other in activating a specific target, such as a gene, a receptor, or an enzyme. In most chimeric molecules, one functionality is designed to provide a high affinity to a designated site, thereby permitting the targeting of the second functionality, which is usually nonspecific. This review focuses on the development of two classes of chimeric medicines, anti-inflammatory and diuretic chimeric agents, both of which incorporate a nitric oxide moiety into the parent pharmacophore.

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673